The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received two or more anti-HER2–based regimens in the metastatic setting.
Fam-trastuzumab deruxtecan-nxki—a human epidermal growth factor receptor 2 (HER2)-directed antibody and topoisomerase inhibitor conjugate—is "the newest treatment option for patients who have progressed on